Lung Cancer

Building on the success of molecularly targeted drugs aimed at relatively small subsets of patients, lung cancer researchers are increasingly aiming at the MET oncogene.

Gary Schwartz, MD, discusses the significance of the PACIFIC trial and applications of immunotherapy for patients with stage III locally advanced disease.

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the PACIFIC trial in patients with non–small cell lung cancer (NSCLC).

Suresh A. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discusses data with pembrolizumab (Keytruda) and chemotherapy in patients with non–small cell lung cancer (NSCLC).

David C. Portnoy, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of driver mutations in the treatment of non–small cell lung cancer (NSCLC).

Suresh A. Ramalingam, MD, discusses the exciting findings from the KEYNOTE-189 and IMpower150 immunotherapy trials in patients with non–small cell lung cancer.

David Mason, MD, addresses the evolving role of surgery for patients with non–small cell lung cancer.

David P. Mason, MD, chief, Thoracic Surgery and Lung Transplantation, Baylor Scott & White Center for Thoracic Surgery, discusses the reliability of the PD-L1 biomarker in non–small cell lung cancer (NSCLC) and its potential applications in surgical approaches.

Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses lingering questions in patients with non–small cell lung cancer (NSCLC).

Kartik Konduri, MD, shares insight on molecular developments, recently discussed clinical trials, and steps the field needs to take to continue moving in a biomarker-driven paradigm of non–small cell lung cancer treatment.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the FLAURA study in patients with lung cancer.

George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.

Ravi Salgia, MD, PhD, discusses the evolving role of ALK-directed therapies for patients with non-small cell lung cancer.

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the KEYNOTE-189 trial in patients with lung cancer.

A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.

Avelumab (Bavencio) missed the primary endpoint of improving overall survival in pretreated patients with non–small cell lung cancer, according to findings from the phase III JAVELIN Lung 200 Trial.

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non-small cell lung cancer (NCSLC).

ALK inhibitors have followed a rapid trajectory from bench to bedside, taking over from chemotherapy as standard frontline treatment for patients with advanced non– small-cell lung cancer with ALK gene rearrangements.

A recent study of oncologists’ use of next-generation sequencing to test for actionable genetic mutations reveals a stark gap between the appropriateness and the actual utilization of these tests.

The FDA has granted a priority review to a new drug application for lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer who have progressed on 1 or more ALK TKIs.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in non-small cell lung cancer.